Dilip Bandyopadhyay
Research interests
-
InterestsRecombinant DNA Technology, Novel Drug Delivery Systems, Antibody Engineering, Recombinant Antibodies, Novel biological Entity
Publications
-
2.71Impact points
MUC1: a target molecule for cancer therapy.
Cancer biology & therapy. 05/2007; 6(4):481-6.
MUC1 is a mucin family protein, overexpressed in more than 90% of breast cancers in an underglycosylated form, exposing the core peptides of the extracellular domain that act as a potential target for antibody-mediated therapy. The highly conserved repeats of 20 amino acids VNTR varies between 20 an... [more] MUC1 is a mucin family protein, overexpressed in more than 90% of breast cancers in an underglycosylated form, exposing the core peptides of the extracellular domain that act as a potential target for antibody-mediated therapy. The highly conserved repeats of 20 amino acids VNTR varies between 20 and 125 depending on the allele. Each tandem repeat contains five potential O-glycosylation sites that have been exploited in designing cancer therapeutics. The core peptides in the tandem repeated VNTR domain are masked in normal cells and become exposed in the cancer cells associated mucins. The characteristics of the MUCI epitopes constituted with the tandem repeats and the carbohydrates present on MUC1 induce immune responses that favor targeted immunotherapy. In addition, aberrant glycosylation also plays an important role in enhancing the internalization of MUC1 into the cytoplasm making MUC1 a very attractive cytoplasmic delivery system of drugs and other therapeutic agents. MUC1 being present on most of the cancers of glandular epithelial origin, appears as a potential target for therapeutic interventions in these cancers.
-
4.95Impact points
Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors.
Molecular cancer therapeutics. 03/2007; 6(2):562-9.
MUC1 is a mucin family protein, overexpressed in more than 90% of breast cancers in an underglycosylated form, exposing the core peptides of the extracellular domain that act as a potential target for antibody-mediated therapy. We have developed an anti-MUC1 scFv antibody from a phage library of mic... [more] MUC1 is a mucin family protein, overexpressed in more than 90% of breast cancers in an underglycosylated form, exposing the core peptides of the extracellular domain that act as a potential target for antibody-mediated therapy. We have developed an anti-MUC1 scFv antibody from a phage library of mice immunized with synthetic peptide MUC1-variable number of tandem repeats. MUC1 binding phages were affinity selected through biopanning using a biotin-streptavidin pull-down method. The selected phage clones showed target-specific binding to MUC1-expressing cells. Fusion of truncated Pseudomonas aeruginosa exotoxin A (ETA) to a high binder, phage-derived scFv clone and bacterial expression and purification of recombinant scFv(MUC1)-ETA immunotoxin were done with good yield and purity. In vitro target-specific cytotoxic activity and target-specific binding of immunotoxin were shown on MUC1-expressing cells and primary breast tumor samples. A truncated ETA fusion protein expressed from the same vector but lacking scFv did not show cytotoxic effects, confirming target specificity. Our results suggest that the scFv(MUC1)-ETA immunotoxin has therapeutic potential and deserves further development and characterization for MUC1-specific breast cancers treatment.
-
2.55Impact points
Detection and evaluation of non-recombinants in cDNA libraries by multiple cloning region PCR.
BioTechniques. 02/2002; 32(1):88-90, 92.
Bacteriophages that are routinely used in cDNA libraries do not require any biological selection for forming plaques. Thus parental non-recombinant phages are always found in variable proportions together with recombinant ones in all cDNA libraries. The presence of non-recombinants in significant pr... [more] Bacteriophages that are routinely used in cDNA libraries do not require any biological selection for forming plaques. Thus parental non-recombinant phages are always found in variable proportions together with recombinant ones in all cDNA libraries. The presence of non-recombinants in significant proportions dilutes the abundance of rare cDNA species and makes library screening difficult. If the exact proportion of non-recombinants in a library were known, then one would screen proportionately more plaques to get a positive clone. In the absence of such information, screening is conventionally conducted on a number that is based on the titer of the library. We have devised a method using the flanking sequences from either side of the multiple cloning region (MCR) of all lambda phage vector derivatives as primers for PCR amplification. A non-recombinant phage produces a fragment equal to the size of the MCR, whereas a recombinant phage produces a fragment larger than the MCR, which is an MCR+ fragment. All cDNA libraries that we have studied show the presence of the MCR fragment (indicating non-recombinants) at variable proportions ranging between 6% and 36% of the total phages present. We also show that their presence negatively influences the retrieval of target cDNA sequences.
